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Abstract
The objectives of this study were to determine (1) the accuracy with which individual patient level 
exposure can be determined and (2) whether a known food effect can be identified in a trial 
simulation of a typical population pharmacokinetic trial. Clinical trial simulations were undertaken 
using NONMEM VII to assess a typical oncology pharmacokinetic trial design. Nine virtual trials 
for each compound were performed for combinations of different level of between-occasion 
variability, number of patients in the trial and magnitude of a food covariate on oral clearance. 
Less than 5% and 20% bias and precision were obtained in individual clearance estimated for both 
abiraterone and nilotinib using this design. This design resulted biased and imprecise population 
clearance estimates for abiraterone. The between-occasion variability in most trials was captured 
with less than 30% of percent bias and precision. The food effect was detectable as a statistically 
significant covariate on oral clearance for abiraterone and nilotinib with percent bias and precision 
of the food covariate less than 20%. These results demonstrate that clinical trial simulation can be 
used to explore the ability of specific trial designs to evaluate the power to identify individual and 
population level exposures,covariate and variability effects.
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INTRODUCTION
In the past twenty years, oral anticancer drug therapy has become more prevalent [1]. Unlike 
intravenous drug administration, orally administered agents undergo absorption from the 
gastrointestinal lumen through the intestinal epithelium into the portal vein and then into the 
systemic circulation. The fraction of an orally administered drug dose that reaches the 
systemic circulation is the drug's oral bioavailability. Significant changes in bioavailability 
will lead to a significant change in drug exposure [2] and thus modified therapeutic and/or 
toxic effects.
One of the most common factors contributing to changes in oral bioavailability is food 
intake [1, 3-4]. The effect of food on oral bioavailability has the potential to cause a 
clinically significant impact on systemic drug exposures that can lead to drug toxicity and/or 
therapeutic failure [5-6]. Furthermore, the alteration of pharmacokinetic profile of several 
standard and investigational anticancer drugs such as busulfan, topotecan and fluorouracil 
caused by food-drug interactions have been previously reported [1]. Quantifying the effect 
of food on drug exposure is, therefore, important when designing a clinical trial for oral anti-
cancer drugs. Additionally, variability between individuals as well as between occasions 
also contributes to variability in drug response. In order to assess the contribution of 
different magnitudes of between-individual and between-occasion variability on drug 
exposure, this study used a population PK modeling approach and Monte Carlo methods to 
simulate a virtual clinical trial of patients who took drug in both the fasted and fed states.
Such a clinical trial simulation framework provides insight as to whether a particular study 
design, with a random sampling schema to reflect a typical clinical practice setting, permits 
the retrieval of pharmacokinetic (PK) parameters and their variability under different 
prandial conditions. In addition, simulation of a clinical trial can assess how patient specific 
covariates, between-individual, and between-occasion variability affect the ability to 
accurately capture individual level exposures. The aim of this study was to evaluate whether 
a pre-defined oncology trial with a sparse drug concentration sampling schedule can 
adequately capture individual level drug exposures, random variability and the food effects 
of two recently approved drugs, abiraterone and nilotinib. To achieve these objectives, a 
virtual cancer study population was simulated with assigned pharmacokinetic 
characteristics, food intake and between-individual as well as between-occasion variability. 
A population pharmacokinetic (Pop PK) approach was utilized to retrieve the Pop PK 
parameters under these conditions and examine whether or not these parameters could be 
adequately retrieved on estimation at both the individual and population level.
MATERIALS AND METHODS
Simulation of Patient Pharmacokinetic Characteristics
Hypothetical patients were created with fasting state Pop PK parameters mimicking those 
found in oncology patients. (See Table 1 for abiraterone [7] and Table 2 for nilotinib [8-9] 
patient characteristics). The Pop PK parameters were assumed to be log normally distributed 
and the parameter values for simulation were obtained or calculated based on literature 
values from a noncompartmental analyses [7-9]. A one compartment model with first order 
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absorption and elimination was assumed as the model structure. Between-individual 
variability of oral clearance (CL/F) and volume of distribution (Vd/F) were based on the 
mean and standard deviation of pharmacokinetic parameters from the above published 
studies. Abiraterone between-individual variability values for oral clearance and volume of 
distribution were 174% and 73%, respectively, in the fasted state and 42.2% and 36%, 
respectively, in the fed state [7]. The between-individual variability of the absorption rate 
constant was assumed to be 20% and a proportional residual error with 30% coefficient of 
variation (CV) was assumed based on literature values for abiraterone [7]. For nilotinib, the 
between-individual variability of oral clearance and volume of distribution values were set 
to 55% and 37% CV, respectively, for both fed and fasting states [9]. A between-individual 
variability for the nilotinib absorption rate constant of 20% and a proportional residual error 
with 10% CV based on the lower limit of quantification of the nilotinib concentration assay 
were assumed [9].
Values of the Pop PK parameters for each hypothetical patient were randomly chosen from 
their respective distributions with a correlation of 0.6 applied between clearance and volume 
of distribution.
Food effects
For both abiraterone and nilotinib, it was assumed that 50% of doses were taken with food 
and that the values of the oral clearance and volume of distribution depended upon whether 
a particular dose was taken with food or without food.
To mimic the actual drug administration protocol for food intake, we considered a different 
food effect in the abiraterone versus nilotinib trials. This was done to test whether the model 
would be able to capture two extreme food effects, the between-individual and between-
occasion variability, and the individual level exposure. For abiraterone, patients in the fed 
prandial state were assumed to have had a high fat meal given the availability of Pop PK 
parameter values in the reference for simulation from this state; therefore, the oral clearance 
and volume of distribution were reduced by 92% and 85%, respectively, if the dose was 
taken with food [7]. In contrast to the abiraterone simulations, patients who were simulated 
as receiving nilotinib were assumed to have ingested a light fat meal and possibly just a 
glass of grape juice 2 hours before or 1 hour after nilotinib was taken. An 18% reduction in 
apparent clearance was introduced to reflect this food effect [9, 10].
Study Design
Patients in the simulated abiraterone trials were randomly assigned to take 1,000 mg once 
daily and patients in the simulated nilotinib trials were assigned to take a 300 or 400 mg 
tablet twice daily in 1:1 fashion. Virtual pharmacokinetic samples for each patient were 
assumed to occur at week 1, week 4, and month 2 and month 3 based on a previously 
established trial sampling schedule from a standard of care clinical follow up approach (see 
Figure 1) after the start of the trial so each individual had a total of 4 measurements (one 
sample obtained on each occasion). This sampling schedule was designed to fit in with the 
standard clinical follow up of the patient. Because the aim of the study was to simulate a 
trial similar to one in clinical practice, the samples were assumed to be withdrawn at random 
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time points during clinic hours. The visit day for each pharmacokinetic sample of each 
hypothetical patient was randomly selected from a discrete distribution with 50% of virtual 
patients having a visit sample drawn on the recommended day, 20% ± 1 day, 20% at ± 2 
days and 10% at ± 3 days from the scheduled visit date. Each clinic visit time was randomly 
selected from a uniform distribution assuming regular office hours from 7am to 6pm. To 
mimic food intake when patients take their medications, a random food covariate was 
generated for each hypothetical patient and sampled for the four different clinic visit 
occasions within each patient.
The hypothetical patients were assigned into trial sizes of 20, 50 or 70 individuals, and each 
trial was replicated 100 times. The same study design was tested using three different 
between-occasion variability levels: 10, 25, and 40% CV on drug clearance.
Population Pharmacokinetic Parameter Estimation
The population pharmacokinetics of the hypothetical patients in each trial were analyzed 
using nonlinear mixed effect modeling software, NONMEM, Version VII (GloboMax_LLC, 
Ellicott City, MD, USA) using Wings for NONMEM, Version 7. One-compartment 
structural model with a proportional residual error model was tested using the first-order 
conditional estimation (FOCE) method. Between-individual variability was tested on oral 
clearance and volume of distribution, and between-occasion variability was tested on oral 
clearance only. The between-individual and between-occasion variability for Pop PK 
parameters were evaluated using an exponential model Pi,k = PTV x eηp,i where Pi,k is the 
parameter estimate for the i th individual after the k th dose administered and PTV is the 
typical value for the parameter at the population level. The variability between the i th 
individual and the population parameter value was described by ηp,i which was assumed to 
be log-normally distributed with a mean of 0 and a variance of ωη p,i2 [11]. The variability 
between the k th occasion of dose administration and the population parameter value was 
described by ηp,k which was assumed to be log-normally distributed with a mean of 0 and a 
variance of ωη p,k2. In addition to the between-individual and between-occasion variability, 
residual variability was described by a proportional error model. That is, Yij = ŷij(1+εij) 
where Yij and Ŷij are the j th observed nilotinib or abiraterone concentration and its 
corresponding model predicted concentration, respectively, with the difference described by 
εij which is assumed to be normally distributed with a mean of 0 and a variance of σ2. In 
order to estimate between-occasion variability in the model, the residual error was fixed in 
the estimation step.
Evaluation of clinical trial designs
The food effect in each trial was evaluated by comparing the fit of a base model with no 
food effects with a model that includes a food effect covariate on oral clearance. The model 
comparison was based on a likelihood ratio test using the objective function value (OFV) 
from NONMEM. The change in the OFV returned by NONMEM is approximately equal to 
−2 × log likelihood. The difference in −2 × log likelihood between two models that are 
nested follows a χ2 distribution. The significance level for identifying the food effect 
corresponded to a decrease in the OFV of greater than 6.63 (p-value≤ 0.01, df=1). The 
power to detect a food effect is the percent of the trials where the population PK analysis 
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demonstrated significant OFV change among the 100 trials in both abiraterone and nilotinib 
and retrieving a food effect value within 20% of the true food effect value.
In addition, to determining whether or not a food effect was detected by the trial design, the 
accuracy and precision of the model for retrieving parameter values of clearance, between-
individual and between-occasion variability was assessed using two statistical standard 
criteria: percent bias and percent precision [12].
At the population level, the bias of each parameter represents the difference between the 
estimated values from the simulated (true) value of the population, and the percent bias is 
the mean predicted error normalized by the simulated value taken from the literature. The 
bias is calculated using the equation shown below:
where Yp,J is the predicted value for the j th trial in total m trials with the same given 
between-occasion variability level and the same sample size, and Ye is the literature value 
we simulated from. The precision was estimated by calculating the root mean square error, 
reflecting the distribution of variance, and the percent precision is the root mean square error 
normalized by the simulated mean. This included the bias and precision of the estimation of 
the food effect.
Parameter estimates at the individual level were evaluated using percent bias and percent 
precision.
where Yp,i and Ye,i are the predicted and simulated values for the ith patient, respectively. n 
represents the number of patients in the trial.
Then, an average of individual percent bias and precision of the m number of trials was 
calculated.
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RESULTS
The percent bias and precision for the population oral clearance for abiraterone ranged from 
−37% to −31% and 36.2% to 38.1%, respectively (Table 3). The average percent bias and 
precision are noticeably smaller in magnitude for individual clearance estimates (range of 
1.2% to 4.4% and 14.5% to 19.9%, respectively). This indicates that the model estimates for 
oral clearance are more accurate and less variable at the individual level compared to the 
population level. Across three between-occasion variability levels (10%, 25%, and 40%), 
21%, 10% and 11% of the abiraterone trials, respectively, retrieved population clearance 
values within 20% of the true value. The ranges of percent bias and precision for between-
individual variability were −45.1% to−42.1% and 42.8% to 46.1, respectively, with minimal 
variations with number of patients in the trial or between-occasion variability. The ranges of 
percent bias and precision of between-occasion variability were −30% to −1.11% and 11.6% 
to 40.7%, respectively (Table3). There was a decrease in both the between-occasion 
variability bias and precision as the number of patients and between-occasion variability 
increased. The known food effect on oral clearance for abiraterone was identified in 100% 
of simulated trials with 20, 50 and 70 patients for the 10%, 25%, and 40% between-occasion 
variability levels. The ranges of percent bias and precision of food effect were 2.01% to 
4.42% and 6.81% to 14.4%, respectively.
The percent bias and precision on the population oral clearance for nilotinib ranged from 
−13.3% to −11.8% and 14.2% to17.0%, respectively (Table 4) and were consistent across 
between-occasion variability levels (10%, 25% and 40%). In contrast to abiraterone, the 
average individual nilotinib oral clearance estimates were significantly more accurate and 
precise than population estimates with the percent bias and precision ranging from −1.9% to 
−0.5% and 4.2% to 8.6%, respectively. Across three between-occasion variability levels 
(10%, 25% and 40%), 86%, 84% and 83% of the nilotinib trials, respectively, retrieved the 
population oral clearance within 20% of the true value. The ranges of percent bias and 
precision of between-individual variability were −9.9% to −7. 9% and 11.3% to 19.4%, 
respectively and ranged from −3.9% to −0.4% and 4.9% to 11.0% for percent bias and 
precision on between-occasion variability. Retrieval of the known food effect in this system 
was observed in 100% of the simulated nilotinib trials with 10% between-occasion 
variability with trial sizes of 25, 50, and 70 patients. For nilotinib trials simulated with 25% 
between-occasion variability, significant food effects on oral clearance were retrieved in 
80% of 20 patient trials, 99% of 50 patient trials, and 100% of 70 patient trials. Nilotinib 
trials simulated with 40% between-occasion variability resulted in significant food effects on 
clearance being retrieved in 50% of 20 patient trials, 78% of 50 patient trials, and 88% of 70 
patient trials. The ranges of percent bias and precision of food effect were - 2.16% to 11.8% 
and 6.3% to 38.8%, respectively.
DISCUSSION
Virtual clinical trials of abiraterone and nilotinib using sparse concentration measurements 
and a population PK sampling time design were simulated to test whether the drug exposure 
of each simulated patient and its variability under different prandial conditions on oral 
clearance for two recently approved drugs would be retrieved accurately and precisely. The 
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trial design is a typical phase II design in the NCI cooperative system and this assessment 
provides and evaluates whether there is value in drawing sparse samples to utilize in 
population pharmacokinetic analysis for the determination of individual drug exposure. It 
was important to assess this particular study design as it is widely used and insight on the 
value of drug concentration sampling under these conditions was unclear. Population as well 
as individual pharmacokinetic parameters for abiraterone, with a large food effect, and 
nilotinib, with a smaller food effect, were well estimated from the virtual trial results. This 
evaluation of whether between-individual and between-occasion variability can be well 
captured with a significant covariate effect on oral clearance (the underlying food effect) at 
different levels of variability on anticancer drug exposure is a novel observation. As the 
prior knowledge of more than 100% between-individual variability was introduced to oral 
clearance in the abiraterone trial, the model estimation of the population oral clearance 
parameter and between-individual variability have relatively poor percent bias and precision 
compared to the nilotinib trial. This is reflected in the power calculation showing that only 
10 to 20% of the trials across three between-occasion variability levels (10, 25, 40%) have 
population oral clearance estimates within 20% of the true value. This finding indicates that 
retrieving population level effects with large between-individual variability may need a 
much larger trial size or more intense sampling schedule or a combination of both.
Between-occasion variability estimates were reasonable considering both percent bias and 
precision were less than 30% in most trial simulations. However, the percent bias and 
precision were relatively poor for the simulated abiraterone trials with 20 patients and 10% 
within-individual variability. One possible explanation of this is that the system is less able 
to capture between-individual variability if the actual variability is small, but the true 
mechanism contributing to this poor bias at 10% between-individual variability is as yet 
unclear.
This model was unable to accurately estimate both residual error and between-occasion 
variability simultaneously. In order to accurately capture the between-individual variability, 
the residual error estimation was fixed to published values. This suggests that more than one 
sample per occasion will be required to distinguish these hierarchies of variability 
simultaneously.
The effects of two important features of such clinical trials were quantified using a 
NONMEM based simulation analysis. These were the power to detect differences in oral 
drug clearance related to the prandial state of the study participants and the degree of 
between-individual variability and sample size. When the between-individual variability was 
set to 25% for a trial with 20 patients, 80% of the simulated nilotonib trials resulted in the 
detection of a statistically significant reduction in oral clearance caused by the food effect. 
The power to detect this food effect on oral drug clearance increased to 100% when the 
number of patients per trial was increased from 20 to 70. At 40% between-individual 
variability, the food effect signal was observed in only 50% of trials with 20 patients, 
increasing to 88% when the number of patients increased to 50. The percent precision also 
indicated that the food effect as a covariate was captured less precisely when between-
occasion variability increased, and the trial sample size was reduced. In contrast, abiraterone 
with a much more substantial food effect (92% reduction in oral clearance) resulted in a 
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power to detect the food effect of 100% in the smallest trial evaluated (20 patients). This 
virtual trial also had 40% between-individual variability and resulted percent bias and 
precision on the Pop PK parameters that were all less than 20%. Using a modeling approach, 
we were able to simulate a complex clinical oncology population pharmacokinetic trial 
setting and capture the between-occasion variability and the magnitude of individual drug 
exposure in the presence of a large food effect for two recently approved oral anti-cancer 
agents. This simulated approach facilitated an early evaluation of the proposed trial design. 
However, clinical trial simulations are generated based on many trial assumptions, and these 
assumptions may include uncertainty. In fact, with different underlying assumptions, the 
simulated outcomes can differ, so multiple scenarios as well as assumptions must be tested 
in order to fully interpret the relevance of the results.
There are limitations to this analysis. First, a dropout model was not incorporated in this 
study design which can potentially contribute to censor events in a 3 month study. The 
simulations also assumed parameter distributions based on available food effect assessment 
in previous non-compartmental analysis. Because of the established sampling schedule, both 
drugs were better estimated with a simplified model structure. Despite this, the model 
provides an approximation of the actual behavior and can capture the trend of the variability 
within the population. In fact, this simplified modeling approach was previously proposed to 
assess the pharmacokinetics of some drug entities in the trials with a relative sparse 
sampling schedule [13-14]. The sampling schedule could also be optimized for the 
identification of food effects and model parameters, but the objective of this work was to 
evaluate pharmacokinetics and food effect given a commonly used sampling schedule. 
Second, non-compliance was not considered in this study design as we assumed that the 
compliance rate should be reasonably controlled in the clinical trial although this will result 
in a higher residual error and between-individual variability than compliance accounted for 
using electronically monitoring [15].
This study emphasizes the importance of addressing trial designs where intensive sampling 
cannot be obtained and yet there is a need to understand the drug exposure characteristics to 
what are otherwise medications with highly variable pharmacokinetic disposition.
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ABBREVIATIONS
PK pharmacokinetic
POP PK population pharmacokinetic
CL oral clearance
V apparent oral volume of distribution
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CV coefficient of variation
FOCE first-order conditional estimation
OFV objective function value
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Figure 1. 
Study schema of abiraterone and nilotinib clinical trials.
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Table 1
Population pharmacokinetic parameters for abiraterone patients
Abiraterone
Parameter Fasting status Mean (SD) Fed status Mean (SD)
Apparent Clearance / bioavailability [CL/F] (L/h) 2650 (4617) 231 (97.7)
Apparent Volume of distribution / bioavailability [Vd/F] (L) 25494 (18670) 4069 (1462)
Absorption rate (1/h) 1.65 (0.33) 1.65 (0.33)
F = oral bioavailability
Absorption rate is fixed to be 1.65 1/h with standard deviation of 0.33.1/h.
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Table 2
Population pharmacokinetic parameters for nilotinib patients
Nilotinib
Parameter Fasting status Mean (SD) Fed status Mean (SD)
Apparent Clearance / bioavailability [CL/F](L/h) 33 (18) 27(15)
Apparent Volume of distribution / bioavailability [Vd/F] (L) 720 (267) 604(181)
Absorption rate (1/h) 0.74 (0.15) 0.74 (0.15)
F = oral bioavailability
Absorption rate is fixed to be 0.74 1/h with standard deviation of 0.15 1/h.
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